Three Days in Milan: Noventure at CPHI 2026
Noventure took part in CPHI Milan 2026, where our team met partners and distributors at stand 20K1 to discuss licensing opportunities for our barrier-based portfolio. [...]
Four Days in Lille: Noventure at ESPGHAN 2026
Last week, Noventure took part in the 58th Annual Meeting of ESPGHAN in Lille, France, where our team presented the Tasectan® paediatric range to clinicians from across Europe and beyond.
Utipro® Plus AF Named Best Women’s Product at the OTC Awards 2026
Utipro® Plus AF has been named Best Women's Product at the OTC & Retail Pharmacy Product Awards 2026 in Ireland, collected by our partner Pamex Limited. [...]
Tasectan and Xilaplus in the new German GPGN Guidelines
Z Gastroenterol 2024; 62(09): 1574-1643 Getting into treatment guidelines is lengthy, especially for new products that need time to gather sufficient scientific and real-life evidence. For this reason, we are glad to announce that Noventure´s mucoprotectants gelatin tannate and xyloglucan have been mentioned on good terms in the new guideline [...]
Partner Devicare, S.L.
We would like to announce our new partnership with Devicare, S.L., to bring Utipro Plus AF into the Spanish market! We’re excited about this new alliance and grateful for the trust placed in us. Interested in exploring business opportunities with us? Contact us! https://noventure.com/contact-us [...]
Tasectan MDR Approved
GREAT NEWS! Noventure is delighted to announce that our medical device Tasectan has just been granted a new CЄ Certificate under MDR Regulation. With 3,7 Mio packs, equivalent to more than 51 Mio of standard units sold through our licensees in 34 countries during 2023, the Tasectan franchise is already [...]
UTIPRO® PLUS AF reaches Central Asia
We are happy to inform that Utipro® Plus AF is ready to land in Central Asia thanks to its very recent registration in Kazakhstan. All evidence supporting the product has been evaluated by the Kazakh Ministry of Health who validated the CE certification of the product and accepted its medical [...]
First launch of UTIPRO® PLUS AF in EUROPE
We are pleased to announce the launch of UTIPRO® PLUS AF in Portugal. Portugal is the first European country in which UTIPRO® PLUS AF has been launched in its composition free from ingredients of animal origin. The product is distributed by Sangool, a Portuguese company specialized in the detailing and the [...]
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants. XILAPLUS® is a class III medical device and complies with the [...]
UTIPRO® PLUS AF strengthens its presence in EUROPE
We are pleased to announce the launch of UTIPRO® PLUS AF in the Republic of Ireland. UTIPRO® PLUS AF, in its composition free from ingredients of animal origin, has been recently launched in the Republic of Ireland, thus further enlarging its presence across Europe. The product is distributed by Pamex, [...]